Wednesday, July 28, 2021
10:36 AM EST – Spectral Medical Inc. : Provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. The Tigris trial end point is a reduction in the 28-day mortality in subjects with septic shock using the PMX hemoperfusion cartridge versus standard of care. Spectral Medical Inc. (T.EDT) shares were unchanged at 0.36.
Stocks in Play: Spectral Medical Inc. , Wed, 28 Jul 2021 10:42:07 EST